Israeli cell therapy demand could be worth $2 billion by 2023
Critical Limb Ischemia (CLI) constitutes a significant burden on the US healthcare system, but an innovative Israeli treatment may be able to fill that requirement.
Biologists work in a laboratory at Pluristem Therapeutics Inc. in Haifa(photo credit: BAZ RATNER/REUTERS)ByILANIT CHERNICK
